Allogene Therapeutics, Inc.
Reports in 18d· 2026-05-15
+47.1% · 90d
$2.25
-0.06 (-2.60%)
After-Hours $2.27(+0.02)
News
(1)April 2026
ALLO Seeks Shareholder Vote to Increase Authorized Shares and Approve Executive Pay
ALLOAllogene Therapeutics, Inc.
# 📜 What This Document Is 📰 This document is a Preliminary Proxy Statement (PRE 14A). Think of it as a comprehensive packet of information and a set of instructions sent out to company shareholders before the annual meeting. Its purpose is not to report quarterly earnings, but rather to get share
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%